ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Boehringer Ingelheim announces FDA acceptance of BLA for spesolimab Pharmaceutical-Business-Review
December 21, 2021Boehringer Ingelheim has announced acceptance of a biologics license application (BLA) and granting of priority review by the US Food and Drug Administration (FDA) for spesolimab in treating generalized pustular psoriasis (GPP) flares.
Pharma Sources Insight January 2025
